
|Videos|September 22, 2016
Metastatic Lung Cancer with Jared M. Weiss, MD: Case 1
Metastatic Lung Cancer with Jared M. Weiss, MD
Advertisement
Weiss case 1:
A 65-year-old man with stage IV NSCLC.
- Tissue biopsy showed EGFR+ adenocarcinoma
- The patient was enrolled in a clinical trial of erlotinib vs erlotinib/bevacizumab
- He was treated with erlotinib for 10 months before developing asymptomatic progression, with slowly growing lesions.
- He was continued on erlotinib for 3 more months; His next scan showed rapid progression.
- Repeat bronchoscopy and mutation testing showed an acquired EGFR T790M mutation
- Patient was subsequently switched to osimertinib
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5






































